Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 109949
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109949
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109949
Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis
Zhao Gao, Shi-Kai Wu, Xuan Jin, Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China
Zheng-Fei Zhou, Department of Hepatic, Biliary, and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China
Xiao-Yan Wang, Tao Song, Department of Pharmacy, Jilin Cancer Hospital, Changchun 130012, Jilin Province, China
Co-first authors: Zhao Gao and Zheng-Fei Zhou.
Author contributions: Gao Z and Zhou ZF wrote the manuscript, contributed equally, and are the joint first authors; Gao Z, Wang XY, and Song T collected and analyzed the data; Zhou ZF and Wu SK analyzed the data; Jin X conceived of the review and edited the manuscript; and all authors read and approved the final manuscript.
Supported by the National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital), No. 2022CR65.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the Peking University First Hospital and Jilin Cancer Hospital, approval No. 2025R0190-0001.
Informed consent statement: The informed consent was waived by the Institutional Review Board.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. jinxuanbdyy@outlook.com
Received: May 28, 2025
Revised: June 23, 2025
Accepted: August 6, 2025
Published online: September 15, 2025
Processing time: 112 Days and 0.5 Hours
Revised: June 23, 2025
Accepted: August 6, 2025
Published online: September 15, 2025
Processing time: 112 Days and 0.5 Hours
Core Tip
Core Tip: This study evaluated the effectiveness of chemoimmunotherapy (CIT) as the first-line regimen for microsatellite stable metastatic colorectal cancer vs standard-of-care (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) in the real world. The efficacy of CIT in microsatellite stable metastatic colorectal cancer could surpass that of standard first-line chemotherapy protocols. Further research is needed to investigate specific clinical characteristics or biomarkers to identify patients who may derive benefit from CIT.